Merck has announced the acquisition of Verona Pharma for 10 billion dollars, strengthening its portfolio of respiratory treatments.
Raluca Ioana Draghici
.webp)
Economy
www.shutterstock.com
Always see our news on Google
Pharmaceutical giant Merck has decided to acquire the British company Verona Pharma for about 10 billion dollars, paying 107 dollars per share, a 23% premium. The strategic move comes amid Merck's desire to diversify its revenue streams, given that the patent for its Keytruda oncology treatment will expire in 2028. This is a continuation of Merck's efforts to expand its portfolio, given previous acquisitions including Prometheus Biosciences.
Sources
Latest News
21:14
Grozăvești CET resumes electricity production, providing 30 MW for the stabilization of the National Energy System.
20:58
Control and propaganda: how the North Korean regime uses the heatwave to project stability
20:41
Diana Buzoianu requested an urgent inspection to verify the prioritization of environmental issues in the counties of Ialomița, Gorj, Suceava, Timiș, and Tulcea.
20:18
Attacks on the Caspian pipeline force Kazakhstan to increase its exports to China
20:17
The Corvin Castle in Hunedoara is undergoing its first complete restoration since 1914, with European funds.
See more news
NEWS ON THE SAME TOPICS
International
AstraZeneca, negotiations with Bristol Myers Squibb for a possible merger that could create a 400 billion dollar group
International
Alphabet announces the sale of shares up to 80 billion dollars to finance the development of artificial intelligence
Personalized news feed, AI-powered search, and notifications in a more interactive experience.
